Quarterly report · Q3
8086.TEDINET S100STZ2
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥439.1bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥545.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥406.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥22.4bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥13.2bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥20.0bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥15.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.8bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥22.1bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥14.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥12.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥13.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥8.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.11T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.03T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.05T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥831.3bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥785.2bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥280.6bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥242.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥240.2bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥79.4bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥89.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥77.44 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.55 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.05 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.69 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.35 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥68.61 | 2023-04-01 → 2023-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.85 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥37.82 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 21.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.3% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-12-31 | ¥3.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-12-31 | ¥642m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥3.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-12-31 | −¥200m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥54.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥54.6bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥19.8bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥345.3bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥340.3bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥5.0bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥35.4bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥96.0bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥54.2bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥41.8bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥5.3bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥48.6bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥43.9bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4.7bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥490.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥438.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥51.5bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥42.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥493.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥439.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥54.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥42.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥3.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥530m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | ¥166m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥28.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥28.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥22.5bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥318.8bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥314.2bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥30.8bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥70.3bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥53.6bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥16.8bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.2bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥42.6bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥38.0bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.5bn |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥431.7bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥405.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥25.9bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥35.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥434.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥406.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥28.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥35.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 445
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 25941000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2621000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 28563000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -28563000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 318823000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 70326000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 42561000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 431712000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3152000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 434864000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -28563000000 | JPY |
| Net sales | Prior1YTDDuration | 406301000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 30788000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 2207000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 2537000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 35533000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 166000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 35699000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -22520000000 | JPY |
| Operating income | Prior1YTDDuration | 13179000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 340345000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 54245000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 43902000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 438493000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 642000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 439135000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 439135000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 5001000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 41775000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 4689000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 51466000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3141000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 54608000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -54608000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 345346000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 96021000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 48592000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 489959000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3783000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 493743000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -54608000000 | JPY |
| Net sales | CurrentYTDDuration | 439135000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 35373000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 5308000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 1638000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 42320000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -200000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |